Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients

Journal of Clinical Neurology (Korea)

Volumn 10, Issue 4, 2014, Pages 289-295

  Fleischer, Vinzenz ^a   Salmen, Anke ^b   Kollar, Susanne ^b   Weyer, Veronika ^a   Siffrin, Volker ^a   Chan, Andrew ^b   Zipp, Frauke ^a   Luessi, Felix ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

Cardiotoxicity; Dose dependency; Mitoxantrone; Multiple sclerosis

Indexed keywords

EID: 84908062263     PISSN: 17386586     EISSN: 20055013     Source Type: Journal    
DOI: 10.3988/jcn.2014.10.4.289     Document Type: Article

References (23)

1. Neuhaus O, Kieseier BC, Hartung HP. Mechanisms of mitoxantrone in multiple sclerosis--what is known? J Neurol Sci 2004;223:25-27.
2. Hartung HP, Gonsette R, König N, Kwiecinski H, Guseo A, Mor-rissey S P, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-2025.
3. Arlin ZA, Silver R, Cassileth P, Armentrout S, Gams R, Daghestani A, et al. Phase I-II trial of mitoxantrone in acute leukemia. Cancer Treat Rep 1985;69:61-64.
4. Mather FJ, Simon RM, Clark GM, Vo n Hoff DD. Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies. Cancer Treat Rep 1987;71:609-613.
5. Praga C, Beretta G, Vigo PL, Lenaz GR, Pollini C, Bonadonna G, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979;63:827-834.
6. Ghalie RG, Mauch E, Edan G, Hartung HP, Gonsette RE, Eisenmann S, et al. A study of therapy-related acute leukaemia after mitoxan-trone therapy for multiple sclerosis. Mult Scler 2002;8:441-445.
7. Rivera VM, Jeffery DR, Weinstock-Guttman B, Bock D, Dangond F. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. BMC Neu-rol 2013;13:80.
8. Le Page E, Leray E, Edan G; French Mitoxantrone Safety Group. Long-term safety profle of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study. Mult Scler 2011;17:867-875.
9. Goffette S, van Pesch V, Vanoverschelde JL, Morandini E, Sindic CJ. Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. J Neurol 2005;252:1217-1222.
10. Zingler VC, Nabauer M, Jahn K, Gross A, Hohlfeld R, Brandt T, et al. Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis. Eur Neurol 2005;54:28-33.
11. Kingwell E, Koch M, Leung B, Isserow S, Geddes J, Rieckmann P, et al. Cardiotoxicity and other adverse events associated with mito-xantrone treatment for MS. Neurology 2010;74:1822-1826.
12. Paul F, Dörr J, Würfel J, Vogel HP, Zipp F. Early mitoxantrone-in-duced cardiotoxicity in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2007;78:198-200.
13. Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, et al. Therapeutic effect of mitoxantrone combined with methyl-prednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112-118.
14. Dörr J, Bitsch A, Schmailzl KJ, Chan A, von Ahsen N, Hummel M, et al. Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurology 2009;73:991-993.
15. Xu X, Persson HL, Richardson DR. Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol 2005;68:261-271.
16. Milleforini E, Gasperini C, Pozzilli C, D’Andrea F, Bastianello S, Trojano M, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244:153-159.
17. Rossato LG, Costa VM, de Pinho PG, Arbo MD, de Freitas V, Vilain L, et al. The metabolic profle of mitoxantrone and its relation with mi-toxantrone-induced cardiotoxicity. Arch Toxicol 2013;87:1809-1820.
18. Cotte S, von Ahsen N, Kruse N, Huber B, Winkelmann A, Zettl UK, et al. ABC-transporter gene-polymorphisms are potential pharmaco-genetic markers for mitoxantrone response in multiple sclerosis. Brain 2009;132(Pt 9):2517-2530.
19. Hasan SK, Buttari F, Ottone T, Voso MT, Hohaus S, Marasco E, et al. Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes. Neurology 2011;76:1059-1065.
20. Chan A, Lo-Coco F. Mitoxantrone-related acute leukemia in MS: an open or closed book? Neurology 2013;80:1529-1533.
21. Bernitsas E, Wei W, Mikol DD. Suppression of mitoxantrone cardio-toxicity in multiple sclerosis patients by dexrazoxane. Ann Neurol 2006;59:206-209.
22. Weilbach FX, Chan A, Toyka K V, Gold R. The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis. Clin Exp Immunol 2004; 135:49-55.
23. U.S. Food and Drug Administration [Internet]. Mitoxantrone Hydro-chloride (marketed as Novantrone and generics) - Healthcare Professional Sheet text version. Rockville, MD: U.S. Food and Drug Administration [cited 2014 Jan 1]. Available from: http://www.fda.gov/drugs/ drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ ucm126445.htm.